A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies
2016 · Investigational New Drugs · 60 citations
https://doi.org/10.1007/s10637-015-0320-9